Interestingly, CART cells were developed to target CSC-antigen EpCAM to eliminate prostate cancer (Deng et al., 2015), demonstrating that EpCAM-specific CART cells had tremendous therapeutic potential for cancer treatment. The gene discussed is EPCAM; the disease is prostate carcinoma.